Close Menu

NEW YORK – Biodesix said today that it has signed an agreement with Thermo Fisher Scientific to develop and seek US Food and Drug Administration approval for a sequencing-based lung cancer liquid biopsy diagnostic test.

Under the agreement, Biodesix will generate analytical and clinical data using Thermo Fisher's Ion Torrent Oncomine Pan-Cancer Cell-Free Assay to apply for premarket approval (PMA) from the FDA. The initiative will focus on patients with advanced non-small cell lung cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Google's Project Nightingale has collected health information on millions of Americans, according to the Wall Street Journal.

An opinion piece at The Hill criticizes the proposed plan to collect DNA samples from migrants at the US border.

Nature News writes that women in chemistry are less likely to have their manuscripts accepted for publication.

In PNAS this week: tRNA fragment signature for chronic lymphocytic leukemia, genomic sites sensitive to ultraviolet radiation in melanocytes, and more.

Nov
13
Sponsored by
Agena Bioscience

This webinar will discuss advances in detecting MET and NTRK variants in tumor samples, which can help clinicians determine the appropriate therapy for cancer patients.

Nov
19
Sponsored by
Stilla

Fluorescent proteins or self-labeling tags are invaluable tools for studying protein dynamics in living cells using fluorescence microscopy. However, quantitative imaging requires physiological levels of expression of the target protein of interest (POI), especially when stoichiometric interactions of the POI need to be investigated.

Dec
02
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Dec
04
Sponsored by
BC Platforms

This webinar will discuss what it takes to begin realizing precision medicine in a comprehensive clinical infrastructure, with insights from the Colorado Center for Personalized Medicine (CCPM).